Daptomycin(dap toe mye’ sin)
Cubicin
PREGNANCY CATEGORY B
Drug Classes
Cyclic lipopeptide antibiotic
Therapeutic Actions
Binds to bacterial cell membranes, causing a rapid depolarization of membrane potential. The loss of membrane potential leads to the inhibition of protein, DNA, and RNA synthesis, which results in bacterial cell death.
Indications
Treatment of complicated skin and skin-structure infections caused by susceptible strains of the following gram-positive bacteria: Staphylococcus aureus (including methicillin-resistant strains), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae, and Enterococcus faecalis (vancomycin-susceptible strains only)
Treatment of S. aureus bloodstream infections, including right-sided endocarditis caused by methicillin-susceptible and methicillin-resistant S. aureus
Unlabeled use: Treatment of vancomycin-resistant Enterococcus faecium
Contraindications and Cautions
Contraindicated with known allergy to daptomycin.
Use cautiously with pregnancy, lactation, renal impairment.
Available Forms
Powder for injection—500 mg/vial
Dosages
Adults
Skin and skin-structure infections: 4 mg/kg IV given over 30 min or as an IV injection over 2 min in 0.9% sodium chloride injection every 24 hr for 7–14 days.
Bacteremia: 6 mg/kg/day IV over 30 min or as an IV injection over 2 min for 2–6 wk or longer.
Pediatric patients
Safety and efficacy not established.
Patients with renal impairment
For patients with CrCl less than 30 mL/min or for those on dialysis, give 4 mg/kg IV once every 48 hr (6 mg/kg for S. aureus bloodstream infections).
Pharmacokinetics
|
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
